Humacyte, Inc. Accrued Professional Fees, Current
Humacyte, Inc. (HUMA) had Accrued Professional Fees, Current of $568.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedProfessionalFeesCurrent · last filed 2026-03-27
- 2025-12-31: Accrued Professional Fees, Current $568.00K.
- 2025-09-30: Accrued Professional Fees, Current $430.00K.
- 2025-06-30: Accrued Professional Fees, Current $591.00K.
- 2025-03-31: Accrued Professional Fees, Current $1.41M.
| Period end | Accrued Professional Fees, Current |
|---|---|
| 2025-12-31 | $568.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $430.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $591.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.41M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $293.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $440.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $665.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $881.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $257.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $242.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $685.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $280.00K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $444.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $263.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $394.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $331.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $294.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $2.71M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $968.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |